Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

Human monoclonal antibodies often display limited thermodynamic and colloidal stabilities.
This behavior hinders their production, and places limitations on the development of novel …

Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …

Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …

The ability of antibodies to bind to target molecules with high affinity and specificity has led
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …

Monoclonal antibodies are the fastest growing class of therapeutics. However, aggregation
limits their shelf life and can lead to adverse immune responses. Assessment and …

Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …

Therapeutic proteins such as antibodies constitute the most rapidly growing class of
pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory …

Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …

Aggregation of mAbs is a crucial concern with respect to their safety and efficacy. Among the
various properties of protein aggregates, it is emerging that their size can potentially impact …